Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
作者信息
Waddington Thomas, Mambetsariev Isa, Pharaon Rebecca, Fricke Jeremy, Baroz Angel Ray, Romo Hannah, Ghanem Bassam, Gray Stacy, Salgia Ravi
机构信息
Department of Medicine, Division of Pulmonary and Critical Care Medicine, City of Hope National Medical Center, Duarte, CA.
Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
出版信息
Clin Lung Cancer. 2021 Sep;22(5):e703-e707. doi: 10.1016/j.cllc.2021.01.009. Epub 2021 Jan 27.
Abstract
摘要
相似文献
1
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.奥拉帕利联合帕博利珠单抗治疗一名携带母系遗传BRCA2胚系变异的年轻患者的治疗潜力：一项研究报告
Clin Lung Cancer. 2021 Sep;22(5):e703-e707. doi: 10.1016/j.cllc.2021.01.009. Epub 2021 Jan 27.
2
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.奥拉帕利联合度伐利尤单抗治疗种系 BRCA 突变转移性乳腺癌患者（MEDIOLA）：一项开放标签、多中心、1/2 期、篮子研究。
Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.
3
Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.卡铂和奥拉帕利在经过多次治疗的携带种系BRCA2和“BRCA样”突变的三阴性转移性乳腺癌中产生完全持久缓解
J Oncol Pract. 2016 Mar;12(3):270-2. doi: 10.1200/JOP.2016.010710.
4
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.奥拉帕利单药治疗携带胚系 BRCA1/2 突变的晚期癌症患者。
J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.
5
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.胚系BRCA2突变的转移性去势抵抗性前列腺癌对奥拉帕利的反应：一例报告
BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.
6
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.一项针对BRCA1或BRCA2突变的HER2阴性晚期乳腺癌一线治疗的I期试验，随后进行两个周期卡铂-奥拉帕利联合治疗，然后奥拉帕利单药治疗与卡培他滨对比的随机II期试验（REVIVAL）：一项随机对照试验的研究方案。
Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.
7
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.奥拉帕利单药治疗伴有胚系 BRCA1/2 突变的复发性晚期卵巢癌患者：反应率和安全性的多研究分析。
Ann Oncol. 2016 Jun;27(6):1013-1019. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8.
8
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.奥拉帕利作为 BRCA1-2 突变的复发性铂类敏感卵巢癌患者的维持治疗：真实世界数据和进展后结局。
Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4.
9
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.胚系BRCA1/2突变的晚期卵巢癌患者对PARP抑制剂奥拉帕尼抗肿瘤反应的基线临床预测指标。
Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.
10
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.奥拉帕利维持治疗在高级别浆液性卵巢癌中的长期应答者：临床和分子特征。
Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.
引用本文的文献
1
Novel germline mutation as a mechanism of resistance to osimertinib in -mutated lung adenocarcinoma: a case report.新型种系突变作为EGFR突变型肺腺癌对奥希替尼耐药的一种机制：病例报告
Transl Lung Cancer Res. 2025 Feb 28;14(2):625-630. doi: 10.21037/tlcr-24-723. Epub 2025 Feb 18.
2
Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.非小细胞肺癌中靶向DNA损伤修复的临床转化：综述
Transl Lung Cancer Res. 2024 Feb 29;13(2):375-397. doi: 10.21037/tlcr-23-742. Epub 2024 Feb 28.
3
BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report.奥拉帕利联合PD-1抑制剂治疗晚期肺鳞状细胞癌中的BRCA2突变：一例报告
Front Oncol. 2023 May 16;13:1190100. doi: 10.3389/fonc.2023.1190100. eCollection 2023.
4
The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer.DNA损伤修复途径改变和同源重组缺陷在肺癌中的预后及治疗潜力
Cancers (Basel). 2022 Oct 28;14(21):5305. doi: 10.3390/cancers14215305.
5
A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers.一种用于治疗BRCA缺陷型癌症的新型PARP抑制剂YHP-836
Front Pharmacol. 2022 Jul 13;13:865085. doi: 10.3389/fphar.2022.865085. eCollection 2022.
本文引用的文献
1
and Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.并基因突变与肺癌：荟萃分析。
Medicina (Kaunas). 2020 Apr 27;56(5):212. doi: 10.3390/medicina56050212.
2
Lung cancer incidence in young women vs. young men: A systematic analysis in 40 countries.年轻女性与年轻男性肺癌发病率的系统分析：40 个国家的研究
Int J Cancer. 2020 Aug 1;147(3):811-819. doi: 10.1002/ijc.32809. Epub 2020 Feb 5.
3
An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome.奥拉帕尼对遗传性乳腺癌-卵巢癌综合征中复发难治性BRCA2突变非小细胞肺癌的显著疗效。
South Asian J Cancer. 2020 Jan-Mar;9(1):6. doi: 10.4103/sajc.sajc_157_19.
4
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.同源重组基因缺陷的非小细胞肺癌细胞对 PARP 抑制剂敏感。
Biochem Biophys Res Commun. 2020 Jan 29;522(1):121-126. doi: 10.1016/j.bbrc.2019.11.050. Epub 2019 Nov 18.
5
Tumour lineage shapes BRCA-mediated phenotypes.肿瘤谱系塑造 BRCA 介导的表型。
Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10.
6
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.度伐利尤单抗联合奥拉帕利治疗伴有和不伴有 DNA 损伤修复突变的转移性去势抵抗性前列腺癌男性患者的疗效。
J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.
7
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.奥拉帕利治疗携种系 BRCA 突变的转移性乳腺癌患者。
N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.
8
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.程序性死亡配体1抑制剂度伐利尤单抗联合聚（ADP-核糖）聚合酶抑制剂奥拉帕利或血管内皮生长因子受体1-3抑制剂西地尼布在女性癌症中的安全性和临床活性：一项剂量递增的I期研究。
J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.
9
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.PARP抑制剂上调PD-L1表达并增强癌症相关免疫抑制。
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720. doi: 10.1158/1078-0432.CCR-16-3215. Epub 2017 Feb 6.
10
The importance of BRCA1 and BRCA2 genes mutations in breast cancer development.BRCA1和BRCA2基因突变在乳腺癌发生发展中的重要性。
Med J Islam Repub Iran. 2016 May 15;30:369. eCollection 2016.
Zotero 插件